THE EFFECTS OF 17β-ESTRADIOL AND TAMOXIFEN ON CELL CYCLE DISTRIBUTION AND F-ACTIN EXPRESSION IN MCF-7 CELLS by Kangaloo, Kirk et al.
Journal of the South Carolina Academy of Science 4 (1):1-12  Fall 2007 
THE EFFECTS OF 17β-ESTRADIOL AND TAMOXIFEN ON CELL CYCLE 
DISTRIBUTION AND F-ACTIN EXPRESSION IN MCF-7 CELLS 
Kirk Kangaloo, Latoya Jenkins, Nicole Clarke, and Samir S. Raychoudhury* 
*Department of Biology, Chemistry, Environmental Health Science, Benedict College, Columbia, SC 
raychoudhurys@benedict.edu 
ABSTRACT 
 A large body of research has focused on the effects of estrogens and anti-estrogens 
such as tamoxifen on cancer tumor growth. Estrogen receptors (ER) refer to ligand-
dependent transcription factors that regulate maintenance, growth and differentiation of 
activities within cells, including MCF-7 cells. Tamoxifen (TAM) molecules compete for 
ER sites, thereby decreasing the effects of estrogen-stimulated breast cancer cell 
proliferation. However, there is also experimental indication that TAM may cause cancer 
in long-term treatment in other reproductive tissues. Of similar interest is the influence of 
17-β estradiol (E2) itself, which is purported to have synergistic effects on cell 
proliferation. In this experiment we have examined the influence of TAM (10-6M and   
10-4M) and E2 (10-6M and 10-4M) on estrogen-responsive MCF-7 cell progression. Flow 
cytometric analysis was utilized to determine the effect on cell cycle distribution in MCF-
7 breast cancer cells upon treatment over 24 hours incubation period. The analysis 
disclosed that TAM (10-4M) and E2 and TAM (10-4M) combined treatments affected the 
G0/G1, S and G2/M phases of MCF-7 cells compared to the controls, and E2 (10-4M) 
showed a decrease in the S phase. It was also observed that treatment with 10-4M TAM 
induced apoptosis. These data suggest that tamoxifen on MCF-7 cells is growth 
inhibitory, cell cycle perturbing and apoptotic, whereas natural estrogen does not share all 
of these responses. Localization of F-actin was examined by indirect 
immunofluorescence microscopy using rhodamine-conjugated phalliodin to label 
filamentous actin. When compared to control, 10-4M 17β-estradiol and 10-4M tamoxifen 
exhibited shortened and less microfilament protein in MCF-7 cells. Western blot analysis 
indicated a marked decrease of F-actin expression in these cells by 10-4M TAM and a 
moderate decrease by 10-4M E2. This provides a useful model to study post-translational 
modification of F-actin regulation of cytoskeleton in ER responsive breast cancer tumor 
cells. 
INTRODUCTION 
For years, the effects of tamoxifen were thought to act through a mechanism of 
blocking estrogen receptors and acting as an anti-estrogen (Kennedy, 1962; Heel et al., 
1978; Kayalar et al., 1996; Forbes, 1997). One in three women who experience metastatic 
mammary cancer responds favorably to treatment with estrogens (Davidson and 
Lippman, 1995). Subsequent use of surgery as a medical approach to treatment of breast 
cancer has surpassed the use of anti-estrogens and aromatase inhibitors (Santen et al., 
1981). However, high dose estrogen (hormone-additive) therapy also generally results in 
tumor regression in postmenopausal female patients with breast cancer that is estrogen 
receptor (ER) positive (Kennedy, 1962). In another study ZR-75-1, an estrogen positive 
breast cancer cell line was investigated utilizing serum-free medium. This research 
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indicated that estradiol has proliferative effects at 10-8 M and 10-9 M, and tamoxifen also 
has stimulatory effects in a dose-dependent manner up to a concentration of 10-7M 
(Cover et al., 1999). Here we see the ability of tamoxifen to mimic the action of 17-β 
estradiol. In a 1993 study, it was determined that under certain physiological conditions 
(decreasing lipoprotein lipase activity and parametrial adipose white tissue wet weight) 
tamoxifen (an anti-estrogen) mimicked the action of estradiol (Wade and Heller, 1993). 
Since tamoxifen mimics and also acts as an anti-estrogen in varying conditions, the 
current study was undertaken to test the effects of tamoxifen and estradiol on the ERα-
positive MCF-7 cell line. Various studies have also shown that the nuclear receptor, ERα 
mediates the expression of the protooncogene c-fos gene as activated by 17-β estradiol in 
ERα positive breast cancer cell lines (Wilding et al., 1988; Van der Burg et al., 1989, 
1990, 1991; Doucas et al., 1991; Weisz and Bresciani, 1993; Bonapace et al., 1996; Duan 
et al., 1998).  
Tamoxifen is a non-steroidal triphenyl ethylene and it is able to structurally conform 
in a manner that makes it look like steroids within the nucleus. It is therefore able to bind 
to the ER receptors, thereby acting as a competitive inhibitor to estradiol (Skidmore et al., 
1972; Jordan and Prestwich, 1977). One mechanism in which anti-estrogens such as 
tamoxifen is believed to function may possibly be by holding the dividing cell in the G1 
phase of the cell cycle, thereby decreasing cell proliferation (Sutherland et al., 1983; 
Osborne et al., 1984). The role of the cell cycle as it pertains to program cell death or 
apoptosis in response to tamoxifen or other hormonal treatment, such as estrogen, is of 
our interest to study. In one 72 hour study, it was determined that for MCF-7 cells, 
mRNA and protein levels associated with ER expression was slightly elevated or 
unregulated with very low concentrations of 10-10M and 10-11M estradiol whereas higher 
concentrations reduced mRNA and protein expression over the 72 hour study period (Ree 
et al., 1989). In this study, we examined the effects of estradiol and its tamoxifen 
counterpart over a 24-hour incubation period. We tested if there were any effects as early 
as one day and the nature of these effects on the cell cycle of MCF-7 cells at relatively 
higher dosages. 
Specifically we treated MCF-7 cells in vitro with dual concentrations of tamoxifen 
and 17β-estradiol (10-4M, 10-6M) as well as combined treatments of tamoxifen and 17-β 
estradiol (10-4M, 10-6M) for a 24-hour incubation period. Flow cytometric analysis was 
conducted to determine the effects of tamoxifen and 17β-estradiol on cell cycle 
distribution. 
Filamentous actin (F-actin) protein is a major intracellular component of human 
cytoskeletal structure that is involved in cell motility and adhesion. Moreover, functions 
of actin filaments include forming a band just beneath the plasma membrane that anchors 
the centrosomes at opposite poles of the cell during mitosis and the generation of 
cytoplasmic streaming in some cells. This protein molecule is also responsible for 
pinching and dividing animal cells apart during cytokinesis. Thus, its regulation is of 
particular interest as an underlying pathway in estrogen responsive cells when exposed to 
estrogens or anti-estrogens. Therefore, we have studied the expression of F-actin in MCF-
7 cells following treatment with E2 and TAM. One observed morphological change in 
apoptosis or PCD is cell condensation and the reorganizing of the cell cytoskeleton 
(Tenniswood, 1992). Cell preparation and execution of apoptosis is associated with 
depolymerization and cleavage of actin as well as other cytoskeletal proteins (Bonfocco 
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et al., 1996; Chen et al., 1996; Kayalar et al., 1996; Levee et al., 1996; Brancholini et al., 
1997; Brown et al., 1997; Caulin et al., 1997; Kothakota et al., 1997; Ku et al., 1997; 
Kruiudering et al., 1998; Porter and Janicke, 1999; Schmeiser and Grand, 1999). For this 
reason, we used indirect immunofluorescence microscopy and western blotting to test 
whether treatments of varying concentrations of tamoxifen and 17β-estradiol had any 
effects on the expression of the cytoskeletal protein, F-actin. 
MATERIALS AND METHODS 
Cell Culture. MCF-7 human mammary adenocarcinoma cell line was obtained from 
American Type Culture Collection (Rockville, MD) and routinely maintained in 
Dulbecco’s Modified Eagle’s/ F-12 media (DMEM; Sigma Chemical Co., St. Louis, MO) 
with 10% charcoal dextran-treated fetal bovine serum (FBS). Cells were cultured in a 5% 
CO2 incubator at 37°C. 
For western blotting, cells (1.0x 10
6
 cells) were cultured on eight 60 mm plates for 24 
hours in 10% charcoal dextran-treated fetal bovine serum (charcoal-stripped FBS) at 
37°C in 5% CO2 and cultured in phenol red-free DMEM for 24 hours. For flow 
cytometry, 5.0 x 10
5
 cells were plated on eight 35mm plates in duplicate. After 24 hours 
incubation, media was replaced with 10% charcoal-stripped serum containing media 
(control), media containing 0.1%DMSO (as vehicle control) or media containing E2 (10
–6 
M, 10
–4 M), TAM (10
-6 M, 10
–4 M), E2+TAM (10
–6 M, 10
–4 M), respectively.  
Flow Cytometry. After 24 hours incubation period, cells were trypsinized (trypsin-
EDTA) and centrifuged at 3500 rpms for five minutes. Cell pellet from each treatment 
group were stained with 1ml Vindelov’s Propidium Iodide (PI) solution (10mM Tris-
HCl, 10µg/ml RNase, 10 mM NaCl, and 0.1 mg PI/ml and 2.0% NP-40) before analyzing 
the DNA ploidy using a FACScan flow-cytometer (XL-MCL; Coulter Corporation, Inc., 
Miami, FL) equipped with a 15mW air-cool laser at 488 nm wavelength. Nuclear DNA 
content was examined based on the intercalation of PI as red fluorescence. 
Fluorescence Microscopy. Cells were grown for 24 hours on square 22 x 22 mm 
coverglasses in respective treatments. Cells were then washed in phosphate buffered 
saline (PBS), pH 7.4, and were fixed in 3.0% paraformaldehyde solution for 10 minutes 
followed by washing twice in PBS containing 0.1% Tween-20. Cells were then incubated 
for 5 minutes at room temperature with 5% bovine serum albumin in PBS with 0.1% 
Triton-X-100. Five microliter of a methanolic stock (containing phallodin) was dissolved 
into 200µl of PBS for each coverslip to be stained. The staining solutions were placed on 
the coverslip for 20 minutes at RT. During incubation coverslips were kept in a covered 
container to prevent evaporation. The stained cells were then washed twice with PBS and 
mounted with Prolong antifade mounting medium (Molecular Probes, Eugene, OR) and 
viewed under a Zeiss fluorescence microscope. 
Western blot Analysis. After the indicated treatments, cell protein was extracted in 
M-Per (Mammalian protein extraction reagent, Pierce, Rockford, IL). Extracts were 
centrifuged at 13,000 rpm for 10 minutes. Protein assay was performed on the 
supernatant using a BCA protein assay kit (Pierce, Rockford, IL). Ten micrograms of 
protein samples were loaded in each lane, and separated by 10 % SDS-PAGE. Proteins 
were transferred at 200 V to Hybond-ECL nitrocellulose membranes (Pharmacia Biotech, 
Buckinghamshire, UK) and blocked for 1 hour at 4˚C in 1% Blotto non-fat dry milk 
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(Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Membranes were incubated with 0.5 
µg/ml monoclonal anti-actin (Sigma Chemical Co., St. Louis, MO) for 1 hr at room 
temperature and subsequently in 1 µg/ml peroxidase conjugated anti-mouse IgG (Fab 
specific) (Sigma Chemical Co., St. Louis, MO) at room temperature. ECL western 
blotting detection analysis (Amersham Biosciences, Buckinghamshire, UK) was used to 
visualize F-actin expression on X-ray film (Eastman Kodak Co., Rochester, NY). 
Statistical Analysis. Flow cytometric experiments were repeated seven times with 
two dishes per treatment and mean and standard error mean (SEM) were calculated. 
Differences between the various treatment groups were analyzed by one-way repeated 
measures analysis of variance (ANOVA). The groups that registered significant 
differences (p<0.05) were analyzed by multiple comparison tests.  Prism 3.02 software 
(Graphpad Inc., San Diego, CA) was utilized to graph and analyze flow cytometry data. 
RESULTS 
     When compared with controls, the cell cycle data indicated that 10-4M E2 significantly 
(p<0.05) downregulated S-phase DNA, while G0/G1 and G2/M DNA remained 
unaffected. 10-4M TAM and E2+TAM combined (10-4 M), decreased (p<0.05) DNA in all 
phases of cell cycle (Table 1) 
 
 
Table 1: Effects of E2, TAM, and E2+TAM on cell cycle analysis in MCF-7 cells as determined 
by flow cytometry. 
 
Phases of cell cycle Treatments 
G0/G1 S G2/M 
Charcoal-stripped 
FBS 
64.6+1.6 12.1+1.3 15.3+1.1 
0.1% DMSO 62.0+1.3 14.5+1.7 14.7+1.1 
E2 10-6M 62.0+1.2
  15.7+1.5 13.4+1.0 
E2 10-4M 68.3+1.7
  6.6+0.8 b 18.9+1.6  
TAM 10-6M 67.5+1.8 12.4+0.6 13.3+1.4 
TAM 10-4M 25.8+8.4
 b 9.8+0.9 b 9.6+1.3 b 
E2+TAM 10-6M 60.1+1.1 17.3+1.3 13.8+1.3 
E2+TAM 10-4M 19.5+5.8
 b 6.6+1.5 b 3.1+0.7 b 
Data represents the mean and SEM from 7 separate experiments. 
 
 
Figure 1 presents results of the representative DNA contents in different phases of 
cell cycle as determined by flow cytometry. Gated histograms demonstrated peaks at the 
cell cycle intervals under the treatment regimen except with TAM 10-4M treatment, 




 Control E210-4M 
 
 TAM 10-4M E2+TAM 10-4M 
 
Figure 1: DNA histograms from the representative treatments as determined by flow cytometry. 
 
 
Photomicrographs presented in Figure 2 showed morphological changes. There was 
reduced growth and larger vacant spaces on cultures following treatment with 10-4M 
TAM (D) and 10-4M E2 (B). Cells treated with 10-4M E2 (B) registered relatively larger 
size and rounded shape with more vacant space and cytoplasmic extensions  
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Figure 2. Phase-contrast photomicrographs of cultured MCF-7 cells incubated for 24 hours in 
medium containing 0.1% DMSO vehicle (A), or in medium with vehicle containing 10-4M E2 
(B), 10-6M E2 (C) and 10-4M TAM (D). (270x). 
 
 
than those in the control cultures (A).  There was rounding of and clumping of cells 
evident in cultures treated with 10-4M TAM (D) and combination of 10-4M E2+TAM. 
Detachment of cells from the substrata was observed with higher concentrations of E2 
(10-4M) and more so with TAM (10-4 M). Cells treated with10-6M E2 (C) showed an 
intense degree of packing and a marked lack of intercellular spaces as compared to even 
the control cultures.  
Localization of F-actin was examined by indirect immunofluorescence microscopy 
using rhodamine-conjugated phalliodin to label filamentous actin. As demonstrated in 
Figure 3, 10-4M E2 (B) and 10-4M TAM (D) exhibited shortened and less 
microfilament. MCF-7 cell cytoskeletal integrity was compromised with both 10-4M E2 
and 10-4M TAM, while with 10-6M E2 (C) the cells exhibited well-organized highly 
intense F-actin staining when compared to that of the control (A). 
Western blot analysis indicated a marked decrease to almost none of F-actin 
expression by 10-4M TAM and a moderate decrease following the 24 hour incubation by 
10-4 M E2, As the concentrations of 17β-estradiol and tamoxifen decreased (10-6M E2 











Figure 3. Photomicrographs rhodamine-phalloidin-labeled filamentous actin localization in 
cultured MCF-7 cells. Cells were cultured on coverslips and incubated for 24 hours in medium 
containing 0.1% DMSO vehicle (A), or in medium with vehicle containing 10-4M E2 (B), 10-6M 








Figure 4: Western blot with 20 µg proteins of rabbit muscle actin as positive control (Lane 1), 
MCF-7 cell lysates following 24 hour treatment with 10-4M TAM (Lane 2),   10-4M E2 (Lane 3), 
10-6M TAM (Lane 4), 10-6M E2 (Lane 5), and in 0.1% DMSO control (Lane 6). 
DISCUSSION 
Tamoxifen, a nonsteriodal triphenyl ethylene has structural conformation such that it 
resembles steroidal molecules located within the nucleus of cells. This enables it to attach 
to the ER receptors, and thus antagonize against molecules as estrogens (Skidmore et al., 
1972; Duan et al., 1998 and 2001). Tamoxifen has also served as a useful anti-estrogen in 
the treatment of human breast cancer for more that twenty years (Heel et al., 1978; 
Osborne et al., 1984; Powel, 1997). Therefore it follows logically that tamoxifen is able 
to inhibit cell growth and induce apoptosis. Various extra cellular signaling molecules 
can upregulate or downregulate mammalian cell proliferation via G1-targeting pathways 
(Jordan and Prestwich, 1977; Draetta, 1994; Sherr, 1996). It has long been recognized 
that tamoxifen possesses growth inhibitory properties in human breast cancer cell growth 
 
Control-0.1%DMSO E2 (10-4M) 
E2 (10-6 M) TAM (10-4M) 
A B 
C D 
   1       2      3     4      5      6 
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and that this can occurs as a result of disrupting the cell cycle as a result of provoking 
estrogen receptor stimulation (Prall et al., 1997). 
We have demonstrated that the acute administration of estradiol and tamoxifen for 
even a shorter period of time does induce regression/alteration of various phases of the 
cell cycle. More specifically, there was a decline in the S phase and G2/M phases with 
relatively higher concentrations of 17β-estradiol (10-4M), and tamoxifen (10-4M) resulting 
in reductions in G0/G1, S and G2/M phases. MCF-7 cells are known to be estrogen 
responsive (DePasquale et al., 1994). Tamoxifen has been known to be an inducer of 
apoptosis in a dose-dependent manner (Ercoli et al., 1998), and also known is the ability 
of estrogens to appear anti-proliferative in its induction of MCF-7 growth at higher 
concentrations of administration (Safe, 1998). The data gathered in this experiment are 
supported by the previously published reports that estrogens have a direct effect on the 
growth of human mammary tumor cells (Horwitz and McGuire, 1978; Lippman, 1981; 
Coezy et al., 1982; Darbe etal., 1983). The possibility of estradiol dependent growth 
resulting from the residual estrogens present in serum may be excluded because 
indigenous estrogens were supposedly removed by using charcoal-dextran treated serum 
in the preparation of  MCF-7 cells. 
When the two concentrations were combined, i.e.; 17β-estradiol and tamoxifen (both 
10-4M), the G0/G1 phase DNA was decreased in MCF-7 cells. However, that did not 
occur with 17β-estradiol (10-4M) only treatment; but tamoxifen (10-4M) alone was able to 
reduce G0/G1 phase DNA. This is a feasible indicator that at this concentrations, the 
tamoxifen molecule is the stronger and more successful competitor for the ERα receptor 
site. 
Additionally, we have indicated that 10-4M tamoxifen altered MCF-7 cell 
morphology, as well as downregulated F-actin very severely. Then, 10-4M 17β-estradiol 
also changed cell shape and decreased actin filament protein moderately (not as severely 
as 10-4M tamoxifen). Here, we see a direct relationship between tamoxifen (Porter and 
Janicke, 1999) and estrogens (Horwitz and McGuire, 1978; Lippman, 1981; Coezy et al., 
1982; Darbe etal., 1983) as it relates to inhibitory effects of cell proliferation of MCF-7 
growth. It is therefore possible that the downregulation and possible cleavage or 
depolymerization of F-actin is instrumental in cell growth inhibition and even apoptotic 
cell death (Bursch et al., 2000). Tamoxifen, at relatively higher concentrations induced 
apoptosis in MCF-7 cells (Ogba et al., 2005). The elevated G2/M phase as observed with 
10-4M 17β-estradiol treatment could be indicative of the G2/M checkpoint attempting to 
accommodate the reduction of genetic material within the cell due to reduced DNA 
synthesis resulting from a depressed S phase. 
In another study in which MCF-7 cells were treated with indol-3-carbinol (I3C) acid-
catalyzed derivatives, growth suppression was observed (Cover et al., 1999).  It was 
noted that suppression was preceded by an arrested G1 and that this reversible disruption 
was accompanied by a downregulation of CDK6 (Cover et al., 1998). This I3C study 
although independent of estrogen receptor signaling indicated the intrinsic role of CDKs 
in cell cycle alteration. However in an estrogen receptor signaling related study, it was 
noted that estrogen-induced activation of CDK4 as well as CDK2 occurring while human 
mammary cancer cells are progressing from the G1 to the S phase was accompanied by 
an up regulated cyclin D1 expression and lower associations between CDK inhibitors and 
the cyclin E-CDK2 complex (Prall et al., 1997).  It is therefore not unreasonable to 
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propose that CDK expression may be directly or indirectly affected by the action of 
higher concentrations of tamoxifen and 17β-estradiol on estrogen receptors. In a recent 
study done in vitro on mice, it was discovered that there exists a positive correlation 
between CDK and CKI [p27 (kip1)] in cells in G0-arrest that contributes to regulating 
cytoskeletal reorganization in neuronal processes. The study utilized RNA interference 
(RNAi) to demonstrate that decreased quantities of p27 reduced the quantity of F-actin 
found in migrating neural processes (Kawauchi et al., 2006). It is therefore feasible to 
postulate that CDK disruptions (and possible cell cycle alterations) can have effects on F-
actin expression. Hence, this may be one possible pathway through which the interaction 
of tamoxifen and estrogens with ERα  receptors can trigger the down regulation of F-
actin as seen in the present study. 
In conclusion, the current study indicates a possible relationship between the down 
regulation of F-actin expression and the ability of tamoxifen and 17β-estradiol to induce 
differentiations and alterations in MCF-7 cell cycle progression. This provides a useful 
model to study post-translational modification of F-actin regulation of cytoskeleton in ER 
responsive breast cancer tumor cells. 
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